Clinical Trials Detalhe
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
General Information
Gender
FEMALE
Age
N/A
Phase
PHASE3
Study Type
INTERVENTIONAL
Location
Pfizer Investigational Site (Coimbra, Portugal)
Pfizer Investigational Site (Coimbra, Portugal)
Pfizer Investigational Site (Evora, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00038467Summary
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Conditions
Breast Neoplasms
Eligibility
Inclusion Criteria: * postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease Exclusion Criteria: * unresectable breast cancer * ER negative primary tumor